Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Immunol Allergy Clin North Am. 2014 Aug;34(3):645–662. doi: 10.1016/j.iac.2014.04.011

Figure 2.

Figure 2

Figure 2

Figure 2

Figure 2

Figure 2

(A) (left) Patient on day 10: abacavir, lamivudine, fosamprenavir and (right) improvement a week later with continued therapy. (B) Patient displays Nevirapine-associated rash at Day 10. (C) Patient with Nevirapine-associated Toxic Epidermal Necrolysis. (D) Patient with Nevirapine-induced DRESS 15 days after the initiation of treatment. (E) Patients displaying Telaprevir-induced rashes of varying severity. Part A shows Grade 1 (mild): treatment is continued. Part B shows Grade 2 (moderate): treatment is continued. Part C shows Grade 3 (severe): treatment is stopped.